Harbin, China--(Newsfile Corp. - December 20, 2018) - China Health Industries Holdings, Inc. (OTCQB: CHHE) ("China Health
Industries", the "Company" or "Us") has completed the strategic transformation from being a traditional health supplement products
manufacturer to a hemp derivative products pioneer. The Company's hemp derivative products have been launched into the Chinese
market since May 2018, including Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Hemp Cosmetics.
For the three months ended September 30, 2018, the sales revenue of our hemp derivative products was $1,620,912, accounting for
75.68% of the Company's total revenue. The hemp derivative products are expected to become the driving force to increase profit in
the fiscal year of 2019, as it is estimated that the sales revenue of the four hemp derivative products is to reach around $6.5
million in the fiscal year of 2019.
The CEO of China Health Industries, Mr. Xin Sun, said: "The four hemp derivative products including Hemp Oil, Hemp Protein
Powder, Hemp Polypeptide and Hemp Cosmetics, which have been available in the market since May 2018, are highly appraised by our
customers. The flowers, leaves, stems and roots of the hemp can be utilized to produce various hemp products. In the upcoming
years, we will invest more resources on expanding our offering of hemp products in the market and developing new hemp products to
meet customers' needs."
About Us
China Health Industries Holdings, Inc. (www.chinahealthindustries.com) is a
holding company vertically integrated with the operations in its subsidiaries in China, specializing in R&D, and production,
marketing and distribution of hemp derivative products, medicines and health supplement products.
China Health owns GMP certified plants and facilities, and manufactures 21 CFDA approved medicines and 14 health supplement
products covering 5 kinds of dosage forms, including soft capsule, hard capsule, tablet, granule and oral liquid. Our product
series covers hemp derivative foods, hemp derivative medicines, externally used medicines and health foods.
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than
statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often
identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and
unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements
are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should
not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of
factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange
Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements
attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other
than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
Company:
Melody Zhang
IR Contact
China Health Industries Holdings, Inc.
Tel: 86-451-88100688
Email: [email protected]
